D. E. Shaw & Co. Inc. Has $14.01 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

D. E. Shaw & Co. Inc. trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 46.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 387,733 shares of the company’s stock after selling 336,949 shares during the period. D. E. Shaw & Co. Inc.’s holdings in SpringWorks Therapeutics were worth $14,009,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Duquesne Family Office LLC increased its holdings in shares of SpringWorks Therapeutics by 21.9% during the 4th quarter. Duquesne Family Office LLC now owns 859,694 shares of the company’s stock worth $31,061,000 after acquiring an additional 154,628 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of SpringWorks Therapeutics in the fourth quarter valued at $3,099,000. BNP Paribas Financial Markets bought a new position in shares of SpringWorks Therapeutics in the fourth quarter valued at about $351,000. Ameriprise Financial Inc. lifted its stake in shares of SpringWorks Therapeutics by 21.7% during the 4th quarter. Ameriprise Financial Inc. now owns 971,099 shares of the company’s stock worth $35,087,000 after buying an additional 173,222 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in shares of SpringWorks Therapeutics during the 4th quarter worth about $1,277,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SWTX shares. Guggenheim restated a “neutral” rating and set a $47.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday. Cowen cut SpringWorks Therapeutics to a “hold” rating in a report on Tuesday, April 29th. TD Cowen reissued a “hold” rating and set a $47.00 target price (down previously from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. HC Wainwright reissued a “neutral” rating and issued a $47.00 target price (down previously from $74.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, April 30th. Finally, Wedbush reaffirmed a “neutral” rating and set a $47.00 price target (down from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, SpringWorks Therapeutics has a consensus rating of “Hold” and an average target price of $52.57.

Insider Activity at SpringWorks Therapeutics

In other news, insider Bhavesh Ashar sold 1,016 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total value of $62,169.04. Following the sale, the insider now owns 62,053 shares of the company’s stock, valued at $3,797,023.07. The trade was a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Badreddin Edris sold 20,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the sale, the chief operating officer now owns 169,712 shares in the company, valued at approximately $9,203,481.76. This represents a 10.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 158,016 shares of company stock worth $9,102,946. Insiders own 7.83% of the company’s stock.

SpringWorks Therapeutics Stock Performance

Shares of SWTX opened at $46.22 on Wednesday. The firm has a market capitalization of $3.47 billion, a P/E ratio of -13.28 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The stock has a 50 day moving average price of $44.16 and a two-hundred day moving average price of $41.91.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). The firm had revenue of $49.09 million for the quarter, compared to analysts’ expectations of $64.19 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. On average, equities analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.